Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ustekinumab to Evaluate a Subject-tailored Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Eligibility Criteria~* Male or female~* Have had a diagnosis of plaque-type psoriasis at least 6 months prior to the first administration of study agent (subjects with concurrent psoriatic arthritis may be enrolled).~* Have plaque-type psoriasis covering at least 10% of their total BSA at screening and at the time of the first administration of study agent.~* Have a PGA score of ≥ 3 at screening and at the time of the first administration of study agent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Group 1: Approved q12w maintenance regimen (Type: EXPERIMENTAL): Active ustekinumab study agent q12 weeks with sham/placebo as necessary to maintain blind
- Group 2: Subject-tailored fixed-interval maintenance regimen (Type: EXPERIMENTAL): Subjects will undergo placebo withdrawal and will receive active study agent up to q24w intervals with sham/placebo injections to maintain the blind.

Based on this trial design, predict the completion outcome and termination type (if applicable).